Citrus flavonoids and lipid metabolism

Current Opinion in Lipidology

Volumn 24, Issue 1, 2013, Pages 34-40

  Assini, Julia M ^a,b   Mulvihill, Erin E ^a,b   Huff, Murray W ^a,b  

^a Department of Biochemistry ^*  (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

atherosclerosis; citrus flavonoids; inflammation; insulin resistance; lipid metabolism

Indexed keywords

7 O METHYLNARINGENIN; APOLIPOPROTEIN B100; AURANTIIN; BIOFLAVONOID; CARNITINE PALMITOYLTRANSFERASE I; CYTOKINE; HESPERIDIN; NARINGENIN; NOBILETIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TANGERETIN; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AORTA; ATHEROGENESIS; ATHEROSCLEROSIS; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CYTOKINE PRODUCTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FATTY LIVER; FOOD INTAKE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY; LIPID ABSORPTION; LIPID METABOLISM; LIVER; METABOLIC PARAMETERS; METABOLIC REGULATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORANGE JUICE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; CITRUS; DYSLIPIDEMIAS; FLAVANONES; FLAVONES; HESPERIDIN; HUMANS; HYPOLIPIDEMIC AGENTS; INFLAMMATION; LIPID METABOLISM; OXIDATION-REDUCTION; PHYTOTHERAPY;

ANIMALIA; CITRUS;

EID: 84872874136     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32835c07fd     Document Type: Review

References (51)

1. Lusis AJ. Atherosclerosis. Nature 2000; 407:233-241.
2. Reyes-Soffer G, Rondon-Clavo C, Ginsberg HN. Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. Expert Opin Pharmacother 2011; 12:1429-1438.
3. Vandenberg BF, Robinson J. Management of the patient with statin intolerance. Curr Atheroscler Rep 2010; 12:48-57.
4. Nissen SE. Atherosclerosis in 2010: new therapeutic insights. Nat Rev Cardiol 2011; 8:70-72.
5. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010; 170:1191-1201.
6. Tsao R. Chemistry and biochemistry of dietary polyphenols. Nutrients 2010; 2:1231-1246.
7. Weng CJ, Yen GC. Flavonoids, a ubiquitous dietary phenolic subclass, exert extensive in vitro antiinvasive and in vivo antimetastatic activities. Cancer Metastasis Rev 2012; 31:323-351.
8. Wedick NM, Pan A, Cassidy A, et al. Dietary flavonoid intakes and risk of type 2 diabetes in US men and women. Am J Clin Nutr 2012; 95:925-933.
9. Hwang SL, Shih PH, Yen GC. Neuroprotective effects of citrus flavonoids. J Agric Food Chem 2012; 60:877-885.
10. Hardcastle AC, Aucott L, Reid DM, Macdonald HM. Associations between dietary flavonoid intakes and bone health in a Scottish population. J Bone Miner Res 2011; 26:941-947.
11. Hooper L, Kroon PA, Rimm EB, et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2008; 88:38-50.
12. Cassidy A, Rimm EB, O'Reilly EJ, et al. Dietary flavonoids and risk of stroke in women. Stroke 2012; 43:946-951.
13. Bokkenheuser VD, Shackleton CH, Winter J. Hydrolysis of dietary flavonoid glycosides by strains of intestinal Bacteroides from humans. Biochem J 1987; 248:953-956.
14. Nielsen IL, Chee WS, Poulsen L, et al. Bioavailability is improved by enzymatic modification of the citrus flavonoid hesperidin in humans: a randomized, double-blind, crossover trial. J Nutr 2006; 136:404-408.
15. Manach C, Williamson G, Morand C, et al. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 2005; 81:230S-242S.
16. Erlund I, Meririnne E, Alfthan G, Aro A. Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. J Nutr 2001; 131:235-241.
17. Mulvihill EE, Huff MW. Citrus flavonoids and the prevention of atherosclerosis. Cardiovasc Hematol Disord Drug Targets 2012 [Epub ahead of print].
18. Miwa Y, Mitsuzumi H, Sunayama T, et al. Glucosyl hesperidin lowers serum triglyceride level in hypertriglyceridemic subjects through the improvement of very low-density lipoprotein metabolic abnormality. J Nutr Sci Vitaminol (Tokyo) 2005; 51:460-470.
19. Jung UJ, Kim HJ, Lee JS, et al. Naringin supplementation lowers plasma lipids and enhances erythrocyte antioxidant enzyme activities in hypercholesterolemic subjects. Clin Nutr 2003; 22:561-568.
20. Demonty I, Lin Y, Zebregs YE, et al. The citrus flavonoids hesperidin and naringin do not affect serum cholesterol in moderately hypercholesterolemic men and women. J Nutr 2010; 140:1615-1620.
21. Park HJ, Jung UJ, Cho SJ et al. Citrus unshiu peel extract ameliorates hyperglycemia and hepatic steatosis by altering inflammation and hepatic glucose- and lipid-regulating enzymes in db/db mice. J Nutr Biochem 2012 [Epub ahead of print].
22. Jeon SM, Park YB, Choi MS. Antihypercholesterolemic property of naringin alters plasma and tissue lipids, cholesterol-regulating enzymes, fecal sterol and tissue morphology in rabbits. Clin Nutr 2004; 23:1025-1034.
23. Pu P, Gao DM, Mohamed S, et al. Naringin ameliorates metabolic syndrome by activating AMP-activated protein kinase in mice fed a high-fat diet. Arch Biochem Biophys 2012; 518:61-70.
24. Cho KW, Kim YO, Andrade JE, et al. Dietary naringenin increases hepatic peroxisome proliferators-activated receptor alpha protein expression and decreases plasma triglyceride and adiposity in rats. Eur J Nutr 2011; 50:81-88.
25. Sharma AK, Bharti S, Ojha S, et al. Up-regulation of PPARgamma, heat shock protein-27 and -72 by naringin attenuates insulin resistance, beta-cell dysfunction, hepatic steatosis and kidney damage in a rat model of type 2 diabetes. Br J Nutr 2011; 106:1713-1723.
26. Mulvihill EE, Allister EM, Sutherland BG, et al. Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor- null mice with diet-induced insulin resistance. Diabetes 2009; 58:2198-2210.
27. Mulvihill EE, Assini JM, Lee JK, et al. Nobiletin attenuates VLDL overproduction, dyslipidemia, and atherosclerosis in mice with diet-induced insulin resistance. Diabetes 2011; 60:1446-1457.
28. Borradaile NM, de Dreu LE, Barrett PH, et al. Hepatocyte apoB-containing lipoprotein secretion is decreased by the grapefruit flavonoid, naringenin, via inhibition of MTP-mediated microsomal triglyceride accumulation. Biochemistry 2003; 42:1283-1291.
29. Borradaile NM, de Dreu LE, Barrett PH, Huff MW. Inhibition of hepatocyte apoB secretion by naringenin: enhanced rapid intracellular degradation independent of reduced microsomal cholesteryl esters. J Lipid Res 2002; 43:1544-1554.
30. Goldwasser J, Cohen PY, Yang E, et al. Transcriptional regulation of human and rat hepatic lipid metabolism by the grapefruit flavonoid naringenin: role of PPARalpha, PPARgamma and LXRalpha. PLoS One 2010; 5:e12399.
31. Li RW, Theriault AG, Au K, et al. Citrus polymethoxylated flavones improve lipid and glucose homeostasis and modulate adipocytokines in fructoseinduced insulin resistant hamsters. Life Sci 2006; 79:365-373.
32. Surmi BK, Hasty AH. Macrophage infiltration into adipose tissue: initiation, propagation and remodeling. Future Lipidol 2008; 3:545-556.
33. Subramanian S, Goodspeed L, Wang SA, et al. Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice. J Lipid Res 2011; 52:1626-1635.
34. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112:1796-1808.
35. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112:1821-1830.
36. Subramanian S, Han CY, Chiba T, et al. Dietary cholesterol worsens adipose tissue macrophage accumulation and atherosclerosis in obese LDL receptordeficient mice. Arterioscler Thromb Vasc Biol 2008; 28:685-691.
37. Stanton MC, Chen SC, Jackson JV, et al. Inflammatory signals shift from adipose to liver during high fat feeding and influence the development of steatohepatitis in mice. J Inflamm (Lond) 2011; 8:8.
38. Lewis KE, Kirk EA, McDonald TO, et al. Increase in serum amyloid a evoked by dietary cholesterol is associated with increased atherosclerosis in mice. Circulation 2004; 110:540-545.
39. Dalgard C, Nielsen F, Morrow JD, et al. Supplementation with orange and blackcurrant juice, but not vitamin E, improves inflammatory markers in patients with peripheral arterial disease. Br J Nutr 2009; 101: 263-269.
40. Milenkovic D, Deval C, Dubray C, et al. Hesperidin displays relevant role in the nutrigenomic effect of orange juice on blood leukocytes in human volunteers: a randomized controlled cross-over study. PloS One 2011; 6:e26669.
41. Buscemi S, Rosafio G, Arcoleo G, et al. Effects of red orange juice intake on endothelial function and inflammatory markers in adult subjects with increased cardiovascular risk. Am J Clin Nutr 2012; 95:1089-1095.
42. Rizza S, Muniyappa R, Iantorno M, et al. Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome. J Clin Endocrinol Metab 2011; 96:E782-E792.
43. Ghanim H, Sia CL, Upadhyay M, et al. Orange juice neutralizes the proinflammatory effect of a high-fat, high-carbohydrate meal and prevents endotoxin increase and Toll-like receptor expression. Am J Clin Nutr 2010; 91:940-949.
44. Soromou LW, Zhang Z, Li R, et al. Regulation of inflammatory cytokines in lipopolysaccharide-stimulated RAW 264.7 murine macrophage by 7-Omethyl- naringenin. Molecules 2012; 17:3574-3585.
45. Miyata Y, Tanaka H, Shimada A, et al. Regulation of adipocytokine secretion and adipocyte hypertrophy by polymethoxyflavonoids, nobiletin and tangeretin. Life Sci 2011; 88:613-618.
46. Leray V, Freuchet B, Le Bloc'h J, et al. Effect of citrus polyphenol- and curcumin-supplemented diet on inflammatory state in obese cats. Br J Nutr 2011; 106 (Suppl 1):S198-S201.
47. Tsai SJ, Huang CS, Mong MC, et al. Anti-inflammatory and antifibrotic effects of naringenin in diabetic mice. J Agric Food Chem 2012; 60:514-521.
48. Lee YS, Cha BY, Choi SS et al. Nobiletin improves obesity and insulin resistance in high-fat diet-induced obese mice. J Nutr Biochem 2012 [Epub ahead of print].
49. Lee CH, Jeong TS, Choi YK, et al. Antiatherogenic effect of citrus flavonoids, naringin and naringenin, associated with hepatic ACAT and aortic VCAM-1 and MCP-1 in high cholesterol-fed rabbits. Biochem Biophys Res Commun 2001; 284:681-688.
50. Mulvihill EE, Assini JM, Sutherland BG, et al. Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice. Arterioscler Thromb Vasc Biol 2010; 30: 742-748.
51. Chanet A, Milenkovic D, Deval C, et al. Naringin, the major grapefruit flavonoid, specifically affects atherosclerosis development in diet-induced hypercholesterolemia in mice. J Nutr Biochem 2012; 23:469-477.